ABNX Fundamental Analysis - ABIONYX PHARMA SA

Name: ABIONYX PHARMA SA (ABNX) Stock
Brand: ABIONYX PHARMA SA
Rating: 7 (3 reviews)

Fundamental Rating

Taking everything into account, ABNX scores 3 out of 10 in our fundamental rating. ABNX was compared to 73 industry peers in the Biotechnology industry. While ABNX seems to be doing ok healthwise, there are quite some concerns on its profitability. ABNX is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ABNX has reported negative net income.

ABNX had a negative operating cash flow in the past year.

In the past 5 years ABNX always reported negative net income.

ABNX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -35.20%, ABNX is in line with its industry, outperforming 46.58% of the companies in the same industry.

The Return On Equity of ABNX (-83.60%) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
ROA	-35.2%
ROE	-83.6%
ROIC	N/A

ROA(3y)-27.55%

ROA(5y)-25.53%

ROE(3y)-53.79%

ROE(5y)-48.87%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ABNX has a Gross Margin (17.78%) which is in line with its industry peers.

ABNX's Gross Margin has declined in the last couple of years.

The Profit Margin and Operating Margin are not available for ABNX so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	17.78%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-21.52%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ABNX does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for ABNX has been increased compared to 1 year ago.

ABNX has more shares outstanding than it did 5 years ago.

ABNX has a better debt/assets ratio than last year.

2.2 Solvency

An Altman-Z score of 11.08 indicates that ABNX is not in any danger for bankruptcy at the moment.

ABNX has a Altman-Z score of 11.08. This is amongst the best in the industry. ABNX outperforms 87.67% of its industry peers.

ABNX has a Debt/Equity ratio of 0.59. This is a neutral value indicating ABNX is somewhat dependend on debt financing.

ABNX has a Debt to Equity ratio (0.59) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0.59
Debt/FCF	N/A
Altman-Z	11.08

ROIC/WACCN/A

WACC8.06%

2.3 Liquidity

A Current Ratio of 1.40 indicates that ABNX should not have too much problems paying its short term obligations.

Looking at the Current ratio, with a value of 1.40, ABNX is in line with its industry, outperforming 41.10% of the companies in the same industry.

ABNX has a Quick Ratio of 1.35. This is a normal value and indicates that ABNX is financially healthy and should not expect problems in meeting its short term obligations.

ABNX has a Quick ratio (1.35) which is in line with its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.4
Quick Ratio	1.35

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for ABNX have decreased strongly by -23.92% in the last year.

The Revenue for ABNX has decreased by -10.91% in the past year. This is quite bad

ABNX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 88.92% yearly.

EPS 1Y (TTM)-23.92%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-2.64%

Revenue 1Y (TTM)-10.91%

Revenue growth 3Y88.92%

Revenue growth 5YN/A

Sales Q2Q%-9.6%

3.2 Future

ABNX is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -51.93% yearly.

Based on estimates for the next years, ABNX will show a very strong growth in Revenue. The Revenue will grow by 69.45% on average per year.

EPS Next Y-68.75%

EPS Next 2Y-48.95%

EPS Next 3Y-14.47%

EPS Next 5Y-51.93%

Revenue Next Year4.35%

Revenue Next 2Y19.33%

Revenue Next 3Y59.17%

Revenue Next 5Y69.45%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ABNX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year ABNX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as ABNX's earnings are expected to decrease with -14.47% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-48.95%

EPS Next 3Y-14.47%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ABNX does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ABIONYX PHARMA SA

EPA:ABNX (10/31/2025, 7:00:00 PM)

4.15

-0.14 (-3.26%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)09-25 2025-09-25

Earnings (Next)03-04 2026-03-04/amc

Inst Owners4.67%

Inst Owner ChangeN/A

Ins Owners39.01%

Ins Owner ChangeN/A

Market Cap144.96M

Revenue(TTM)4.33M

Net Income(TTM)-4599000

Analysts85

Price Target10.97 (164.34%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)-22.73%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)4.35%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	33.51
P/FCF	N/A
P/OCF	N/A
P/B	26.35
P/tB	2735.09
EV/EBITDA	N/A

EPS(TTM)-0.13

EYN/A

EPS(NY)-0.36

Fwd EYN/A

FCF(TTM)-0.1

FCFYN/A

OCF(TTM)-0.1

OCFYN/A

SpS0.12

BVpS0.16

TBVpS0

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-35.2%
ROE	-83.6%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	17.78%
FCFM	N/A

ROA(3y)-27.55%

ROA(5y)-25.53%

ROE(3y)-53.79%

ROE(5y)-48.87%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-21.52%

GM growth 5YN/A

F-Score3

Asset Turnover0.33

Health

		Industry Rank	Sector Rank
Debt/Equity	0.59
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	168.8%
Cap/Sales	4.88%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.4
Quick Ratio	1.35
Altman-Z	11.08

F-Score3

WACC8.06%

ROIC/WACCN/A

Cap/Depr(3y)90.3%

Cap/Depr(5y)216.62%

Cap/Sales(3y)2.6%

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-23.92%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-2.64%

EPS Next Y-68.75%

EPS Next 2Y-48.95%

EPS Next 3Y-14.47%

EPS Next 5Y-51.93%

Revenue 1Y (TTM)-10.91%

Revenue growth 3Y88.92%

Revenue growth 5YN/A

Sales Q2Q%-9.6%

Revenue Next Year4.35%

Revenue Next 2Y19.33%

Revenue Next 3Y59.17%

Revenue Next 5Y69.45%

EBIT growth 1Y-41.2%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-124.07%

EBIT Next 3Y-22.39%

EBIT Next 5Y-62.81%

FCF growth 1Y-49.49%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-48.65%

OCF growth 3YN/A

OCF growth 5YN/A

ABIONYX PHARMA SA / ABNX.PA FAQ

What is the ChartMill fundamental rating of ABIONYX PHARMA SA (ABNX.PA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to ABNX.PA.

Can you provide the valuation status for ABIONYX PHARMA SA?

ChartMill assigns a valuation rating of 0 / 10 to ABIONYX PHARMA SA (ABNX.PA). This can be considered as Overvalued.

What is the profitability of ABNX stock?

ABIONYX PHARMA SA (ABNX.PA) has a profitability rating of 1 / 10.

Can you provide the financial health for ABNX stock?

The financial health rating of ABIONYX PHARMA SA (ABNX.PA) is 4 / 10.

ABIONYX PHARMA SA (ABNX.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

ABIONYX PHARMA SA / ABNX.PA FAQ

What is the ChartMill fundamental rating of ABIONYX PHARMA SA (ABNX.PA) stock?

Can you provide the valuation status for ABIONYX PHARMA SA?

What is the profitability of ABNX stock?

Can you provide the financial health for ABNX stock?